Original article
Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1

https://doi.org/10.1016/S0163-4453(97)90953-1Get rights and content

Procalcitonin (ProCT) is a recently described marker of severe sepsis. It was decided to assess the value of proCT as a marker of secondary infection in patients infected with HIV-1. ProCT plasma levels were measured by immunoluminometric assay in a prospective study in 155 HIV-infected individuals: 102 asymptomatic and 53 with fever or suspected secondary infections.

The baseline plasma level of ProCT was low (0.5 ng/ml ± 0.37), even in the latest stages of the disease, and did not differ from the values of healthy subjects (0.54 ng/ml ± 0.08). EDTA-treated whole blood was collected from patients before starting specific antimicrobial therapy. No elevation of ProCT level was detected in HIV-infected patients with evolving secondary infections including PCP (n = 4), cerebral toxoplasmosis (n = 4), viral infections (n = 9), mycobacterial infections (n = 5), localized bacterial (n = 12) and fungal infections (n = 4), malignancies (n = 3), and in various associated infectious and non-infectious febrile events (n = 13). All these plasma values were lower than 2.1 ng/ml.

In contrast, high ProCT plasma levels were detected in one HIV-infected patient with a septicaemic Haemophilus influenzae infection (16.5 ng/ml) and another one with a septicaemic Pseudomonas aeruginosa infection (44.1 ng/ml). ProCT values decreased rapidly under appropriate therapy.

ProCT seems to be a specific marker of bacterial sepsis in HIV-infected patients, as no increase in other secondary infections could be detected in those patients. A rapid determination of ProCT level could be useful to confirm or refute bacterial sepsis for a better management of febrile HIV-infected patients.

References (13)

There are more references available in the full text version of this article.

Cited by (0)

This work was presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San-Francisco, 1995, poster 1255).

View full text